Literature DB >> 29678944

The clinical significance of oropharyngeal cultures in young children with cystic fibrosis.

Oded Breuer1,2,3, Daan Caudri1,2,4,3, Lauren Akesson1,5,6, Sarath Ranganathan5,6,7,8, Stephen M Stick1,2, André Schultz1,2,9.   

Abstract

In children with cystic fibrosis (CF) the associations between oropharyngeal swabs (OPSs) for detection of Pseudomonas and lung disease have not been evaluated.OPS and bronchoalveolar lavage (BAL) samples were obtained annually in children with CF from 2005 to 2017. OPS test characteristics were calculated using BAL as "gold standard". Results were related to lung inflammation (BAL neutrophil elastase and interleukin-8), structural lung disease (chest computed tomography PRAGMA-CF (Perth-Rotterdam Annotated Grid Morphometric Analysis for CF) scores), respiratory exacerbations and future detection of Pseudomonas on BAL.From 181 patients, 690 paired OPS-BAL cultures were obtained. Prevalence of Pseudomonas in BAL was 7.4%. OPS sensitivity was 23.0% and specificity was 91.4%, reducing the post-test probability for a positive BAL following a negative OPS to 6.3%. Pseudomonas on OPS was not associated with lung inflammation or respiratory exacerbations, but was weakly associated with current PRAGMA-CF %Disease score (p=0.043). Pseudomonas on BAL was associated with positive neutrophil elastase (OR 4.17, 95% CI 2.04-8.53; p<0.001), increased interleukin-8 (p<0.001), increased all baseline PRAGMA computed tomography scores (p<0.001), progression of PRAGMA computed tomography scores (p<0.05) and increased risk of respiratory exacerbations (incidence rate ratio 2.11, 95% CI 1.15-3.87; p=0.017).In children with CF OPSs only marginally change the probability of detecting lower airway Pseudomonas and are not associated with lung disease indices nor exacerbations risk.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29678944     DOI: 10.1183/13993003.00238-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Selective Sampling of the Lower Airway in Children with Cystic Fibrosis: What Are We Missing?

Authors:  Andrew Turnbull; Dominic Hughes; Jane Davies
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

2.  Reply to Turnbull et al. and to Hulme et al.

Authors:  Oded Breuer; Andre Schultz; Lidija Turkovic; Nicholas de Klerk; Anthony D Keil; Siobhain Brennan; Joanne Harrison; Colin Robertson; Philip J Robinson; Peter D Sly; Sarath Ranganathan; Stephen M Stick; Daan Caudri
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

3.  Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis.

Authors:  Christophe Marguet; Véronique Houdouin; Isabelle Pin; Philippe Reix; Frédéric Huet; Marie Mittaine; Sophie Ramel; Nathalie Wizla-Derambure; Michel Abely; Marie-Laure Dalphin; Michael Fayon; Tiphaine Bihouée; Muriel Le Bourgeois; Eric Deneuville; Harriet Corvol; Muriel Laurans; Laure Couderc; Evelyne Leroux; Ludovic Lémée
Journal:  ERJ Open Res       Date:  2021-03-08

Review 4.  Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.

Authors:  Christina S Thornton; Nicole Acosta; Michael G Surette; Michael D Parkins
Journal:  J Pediatric Infect Dis Soc       Date:  2022-09-07       Impact factor: 5.235

Review 5.  Monitoring disease progression in childhood bronchiectasis.

Authors:  Kathryn A Ramsey; André Schultz
Journal:  Front Pediatr       Date:  2022-09-16       Impact factor: 3.569

6.  Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.

Authors:  Nicole Mayer-Hamblett; George Retsch-Bogart; Margaret Kloster; Frank Accurso; Margaret Rosenfeld; Gary Albers; Philip Black; Perry Brown; AnneMarie Cairns; Stephanie D Davis; Gavin R Graff; Gwendolyn S Kerby; David Orenstein; Rachael Buckingham; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2018-11-01       Impact factor: 30.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.